Jia-Run Lin

Jia-Run Lin

Auto-generated profile, based on publicly available information

Jia-Run Lin

Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JLJia-Run Lin
Jia-Run Lin
DHDuan-Duan Han
Duan-Duan Han
WWWei Wei
Wei Wei
QZQin Zeng
Qin Zeng
ZRZi-Xuan Rong
Zi-Xuan Rong
ZDZhong-Yi Dong
Zhong-Yi Dong
Aspirin has shown potential for cancer prevention, but a recent large randomized controlled trial found no evidence for a reduction in cancer risk. Given the anti-inflammatory effects of aspirin, systemic inflammatory diseases (SID), such as osteoporosis, cardiovascular diseases, and metabolic diseases, could potentially modify the aspirin-cancer link. To investigate the impact of aspirin in people with SIDs, we conducted an observational study on a prospective cohort of 478,615 UK Biobank participants. Individuals with at least one of the 41 SIDs displayed a higher cancer risk than those without SIDs. Regular aspirin use showed protective effects exclusively in patients with SID, contrasting an elevated risk among their non-SID counterparts. Nonetheless, aspirin use demonstrated preventative potential only for 9 of 21 SID-associated cancer subtypes. Cholesterol emerged as another key mediator linking SIDs to cancer risk. Notably, regular statin use displayed protective properties in patients with SID but not in their non-SID counterparts. Concurrent use of aspirin and statins exhibited a stronger protective association in patients with SID, covering 14 common cancer subtypes. In summary, patients with SIDs may represent a population particularly responsive to regular aspirin and statin use. Promoting either combined or individual use of these medications within the context of SIDs could offer a promising chemoprevention strategy. Significance: Individuals with systemic inflammatory diseases derive chemoprotective benefits from aspirin and statins, providing a precision cancer prevention approach to address the personal and public challenges posed by cancer.

29 October 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
ZZZhenhua Zhou
Zhenhua Zhou
JLJia-Run Lin
Jia-Run Lin
JLJiaxin Li
Jiaxin Li
XHXintong Huang
Xintong Huang
LYLu Yuan
Lu Yuan
LLLaiyu Liu
Laiyu Liu
Background: Checkpoint inhibitor pneumonitis (CIP) is among the most lethal immune-related adverse events in patients with cancer receiving immunotherapy. This study aims to characterize the lung microbiome in patients with CIP and evaluate its diagnostic potential. Methods: In a prospective clinical trial ( NCT06192303 ), bronchoalveolar lavage fluid samples (BALF) were obtained from 38 patients presenting clinical symptoms and radiographic evidence of pneumonitis following immunotherapy. The cohort included 14 cases of pure-type CIP (PT-CIP), 14 cases of mixed-type CIP, and 10 cases of pulmonary infection (PI). Metagenomic next-generation sequencing (mNGS) of BALF was employed to delineate the lung microbiota profiles. Using linear discriminant analysis effect size, we discerned characteristic microbiota among the three groups and further explored the associations of signature microbiota with host immune-inflammatory markers. Functional enrichment analysis revealed potential metabolic reprogramming and differences in biological functions between patients with CIP and PI. Finally, leveraging four machine-learning models, we ascertained the clinical value of BALF microbiota profiles in diagnosing CIP. Results: The composition of lung microbiota differed significantly between patients with CIP and PI. Microbial taxa, such as Porphyromonas , Candida , Peptostreptococcus , Treponema , and Talaromyces, exhibited distinct abundance patterns across the three groups. Correlation analysis revealed a significant positive relationship between Candida abundance and host immune-inflammatory markers, such as neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, monocyte-lymphocyte ratio, and systemic immune inflammation index. In contrast, Porphyromonas demonstrated a significant negative correlation. Compared with the patients with PT-CIP, the lung microbiota of patients with PI exhibited a more diverse biological and metabolic profile. Additionally, machine learning models based on BALF microbiota profiles could accurately diagnose CIP, with the decision tree model showing the best diagnostic performance (area under the curve: 0.88). Conclusions: Our study represents the unique characterization of the lung microbiota profiles across distinct CIP subtypes and establishes a diagnostic model for CIP based on the decision tree. These findings emphasize the value of BALF mNGS in improving the diagnosis of CIP.

4 June 2024
Verified
Other
Open access
JLJia-Run Lin
Jia-Run Lin
DHDuan-Duan Han
Duan-Duan Han
WWWei Wei
Wei Wei
QZQin Zeng
Qin Zeng
ZRZi-Xuan Rong
Zi-Xuan Rong
ZDZhong-Yi Dong
Zhong-Yi Dong
Supplementary Fig. S1-13,Supplementary Table S1-15

4 June 2024
Verified
Other
Open access
JLJia-Run Lin
Jia-Run Lin
DHDuan-Duan Han
Duan-Duan Han
WWWei Wei
Wei Wei
QZQin Zeng
Qin Zeng
ZRZi-Xuan Rong
Zi-Xuan Rong
ZDZhong-Yi Dong
Zhong-Yi Dong
Aspirin has shown potential for cancer prevention, but a recent large randomized controlled trial found no evidence for a reduction in cancer risk. Given the anti-inflammatory effects of aspirin, systemic inflammatory diseases (SID), such as osteoporosis, cardiovascular diseases, and metabolic diseases, could potentially modify the aspirin-cancer link. To investigate the impact of aspirin in people with SIDs, we conducted an observational study on a prospective cohort of 478,615 UK Biobank participants. Individuals with at least one of the 41 SIDs displayed a higher cancer risk than those without SIDs. Regular aspirin use showed protective effects exclusively in patients with SID, contrasting an elevated risk among their non-SID counterparts. Nonetheless, aspirin use demonstrated preventative potential only for 9 of 21 SID-associated cancer subtypes. Cholesterol emerged as another key mediator linking SIDs to cancer risk. Notably, regular statin use displayed protective properties in patients with SID but not in their non-SID counterparts. Concurrent use of aspirin and statins exhibited a stronger protective association in patients with SID, covering 14 common cancer subtypes. In summary, patients with SIDs may represent a population particularly responsive to regular aspirin and statin use. Promoting either combined or individual use of these medications within the context of SIDs could offer a promising chemoprevention strategy.Significance:Individuals with systemic inflammatory diseases derive chemoprotective benefits from aspirin and statins, providing a precision cancer prevention approach to address the personal and public challenges posed by cancer.

4 June 2024
Verified
Other
Open access
JLJia-Run Lin
Jia-Run Lin
DHDuan-Duan Han
Duan-Duan Han
WWWei Wei
Wei Wei
QZQin Zeng
Qin Zeng
ZRZi-Xuan Rong
Zi-Xuan Rong
ZDZhong-Yi Dong
Zhong-Yi Dong
Aspirin has shown potential for cancer prevention, but a recent large randomized controlled trial found no evidence for a reduction in cancer risk. Given the anti-inflammatory effects of aspirin, systemic inflammatory diseases (SID), such as osteoporosis, cardiovascular diseases, and metabolic diseases, could potentially modify the aspirin-cancer link. To investigate the impact of aspirin in people with SIDs, we conducted an observational study on a prospective cohort of 478,615 UK Biobank participants. Individuals with at least one of the 41 SIDs displayed a higher cancer risk than those without SIDs. Regular aspirin use showed protective effects exclusively in patients with SID, contrasting an elevated risk among their non-SID counterparts. Nonetheless, aspirin use demonstrated preventative potential only for 9 of 21 SID-associated cancer subtypes. Cholesterol emerged as another key mediator linking SIDs to cancer risk. Notably, regular statin use displayed protective properties in patients with SID but not in their non-SID counterparts. Concurrent use of aspirin and statins exhibited a stronger protective association in patients with SID, covering 14 common cancer subtypes. In summary, patients with SIDs may represent a population particularly responsive to regular aspirin and statin use. Promoting either combined or individual use of these medications within the context of SIDs could offer a promising chemoprevention strategy.Significance:Individuals with systemic inflammatory diseases derive chemoprotective benefits from aspirin and statins, providing a precision cancer prevention approach to address the personal and public challenges posed by cancer.

4 June 2024
Verified
Other
Open access
JLJia-Run Lin
Jia-Run Lin
DHDuan-Duan Han
Duan-Duan Han
WWWei Wei
Wei Wei
QZQin Zeng
Qin Zeng
ZRZi-Xuan Rong
Zi-Xuan Rong
ZDZhong-Yi Dong
Zhong-Yi Dong
Supplementary Fig. S1-13,Supplementary Table S1-15